Scholarlink

<p>Clozapine is one of the oldest antipsychotic drugs, the first atypical neuroleptic drug, and can be found in the World Health Organization’s list of essential drugs. The precise mechanism of action of clozapine as an antipsychotic is not known. However, clozapine binds to many proteins in vitro. The objective of this study was to investigate the role of the dopamine D<sub>1</sub> receptor as a possible explanation for the cardiac side effects of clozapine. To this end, the hypothesis was tested that clozapine reduces the positive inotropic or positive chronotropic effects mediated by human cardiac dopamine D<sub>1</sub> receptors using a novel transgenic mouse model with cardiac myocyte-specific expression of the human dopamine D<sub>1</sub> receptor (D<sub>1</sub>-TG). The force of contraction in the left (LA) and right (RA) atria of adult D<sub>1</sub>-TG mice and, as a control, wild-type (WT) mice was measured and compared to human right atrial preparations (HAP), which were obtained from adult patients with coronary heart disease during cardiac surgery. In the presence of propranolol, which was used to block endogenous β-adrenoceptors, dopamine increased the force of contraction in LA and elevated the beating rate in RA from D<sub>1</sub>-TG. The effects in RA, but not in LA, were antagonized by clozapine. The effects were more pronounced in the presence of haloperidol, a typical antipsychotic drug. This drug was studied for comparison in mouse atrial preparations and was found to antagonize the effects of dopamine in both LA and RA. Furthermore, clozapine decreased dopamine receptor–stimulated contractile force in HAP. These findings suggest that the D<sub>1</sub> receptor antagonism may contribute to cardiac side effects associated with clozapine in patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clozapine acts as an antagonist of human dopamine D1 receptors in the atrium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Lina Maria Rayo Abella,
  • Britt Hofmann,
  • Tom Lars Neubert,
  • Joachim Neumann,
  • Ulrich Gergs

摘要

Clozapine is one of the oldest antipsychotic drugs, the first atypical neuroleptic drug, and can be found in the World Health Organization’s list of essential drugs. The precise mechanism of action of clozapine as an antipsychotic is not known. However, clozapine binds to many proteins in vitro. The objective of this study was to investigate the role of the dopamine D1 receptor as a possible explanation for the cardiac side effects of clozapine. To this end, the hypothesis was tested that clozapine reduces the positive inotropic or positive chronotropic effects mediated by human cardiac dopamine D1 receptors using a novel transgenic mouse model with cardiac myocyte-specific expression of the human dopamine D1 receptor (D1-TG). The force of contraction in the left (LA) and right (RA) atria of adult D1-TG mice and, as a control, wild-type (WT) mice was measured and compared to human right atrial preparations (HAP), which were obtained from adult patients with coronary heart disease during cardiac surgery. In the presence of propranolol, which was used to block endogenous β-adrenoceptors, dopamine increased the force of contraction in LA and elevated the beating rate in RA from D1-TG. The effects in RA, but not in LA, were antagonized by clozapine. The effects were more pronounced in the presence of haloperidol, a typical antipsychotic drug. This drug was studied for comparison in mouse atrial preparations and was found to antagonize the effects of dopamine in both LA and RA. Furthermore, clozapine decreased dopamine receptor–stimulated contractile force in HAP. These findings suggest that the D1 receptor antagonism may contribute to cardiac side effects associated with clozapine in patients.